IDEA Collider

In this episode of Idea Collider, host Mike Rea interviews Dr. Christian Rommel from Bayer. Dr. Rommel discusses his journey in molecular oncology from the Max Planck Institute, through roles at Roche, to overseeing global R&D at Bayer. He shares insights on turning scientific discovery into novel medicines, collaboration between scientists and commercial teams, and the importance of maintaining scientific integrity. Dr. Rommel also delves into the impact of AI in drug development, the potential of genetic medicines, and the complexities of launching new medicines on a global scale. The conversation also touches on embracing failure, internal and external partnerships, and the evolving landscape of clinical translation. 00:00 Introduction and Guest Welcome00:25 Christian Rommel's Journey in Oncology03:02 The Importance of Collaboration in Innovation05:16 Balancing Risk and Reward in Drug Development18:07 The Role of AI and Data in Modern R&D22:33 Partnerships and External Learning26:16 Balancing Legacy and Innovation in Biotech27:18 Global Expansion and Leadership Diversity27:27 Courage in Biotech Management27:54 Inspiration from Roche Genentech30:26 Commitment to Product Supply and Market Readiness32:23 Challenges of Global Launches35:53 Emerging Trends in Pharma: AI and Genetic Medicines42:20 Decision-Making in Pharma47:30 Reflections on Academic and Professional Journey Don't forget to Like, Share, Subscribe, Rate, and Review! Keep up with Christian Rommel;LinkedIn: https://www.linkedin.com/in/christian-rommel/Website: https://www.bayer.com/en/innovation/science-research-and-innovation Follow Mike Rea On;Website: https://www.ideapharma.com/X: https://x.com/ideapharmaLinkedIn: https://www.linkedin.com/in/bigidea/ Listen to more fantastic podcast episodes: https://podcast.ideapharma.com/

In this insightful episode of IDEA Collider, Mike welcomes Mathai Mammen, Chairman and CEO of Parabilis Medicines. Mathai shares his extensive journey through academia, MD PhD program at Harvard, co-founding Theravance, and leadership roles at Merck and J&J. They delve into Mathai's innovative approach to creating transformative medicines, navigating the biotech industry, and the unique challenges of targeting 'undruggable' proteins. They also discuss the role of AI in drug discovery, the importance of strategic risk, and fostering team resilience and spirit in both large and small pharma companies. 00:00 Introduction and Guest Background00:56 Founding Thebans and Career Highlights01:43 Leadership at Merck and J&J02:18 Innovative Approaches at Parabilis Medicines04:09 Defining and Tackling Undruggable Targets09:27 Multivalent Drug Design and Bispecifics13:53 AI and Data Science in Drug Development19:28 Building and Leading World-Class Teams25:41 The Importance of Holding Conviction as an Entrepreneur26:25 Learning from Setbacks in the Biotech Industry30:10 Challenges and Innovations in Drug Development32:28 Navigating the Ups and Downs of the Biotech Industry36:02 The Mission and Future of Parabilis40:35 Personal Reflections and Advice for Entrepreneurs46:46 Book Recommendations and Closing Thoughts Don't forget to Like, Share, Subscribe, Rate, and Review! Keep up with Mathai Mammen;LinkedIn: https://www.linkedin.com/in/mathai-mammen/Website: https://parabilismed.com/ Follow Mike Rea On;Website: https://www.ideapharma.com/X: https://x.com/ideapharmaLinkedIn: https://www.linkedin.com/in/bigidea/ Listen to more fantastic podcast episodes: https://podcast.ideapharma.com/

In this episode of Idea Collider, host Mike Rea interviews Paul Peter Tak, CEO of Candel Therapeutics, discussing his remarkable journey from a clinician in Amsterdam to leading cutting-edge biotech companies. Paul shares pivotal moments in his career, the challenges of transitioning from academia to big pharma, and the innovative principles he applied. He dives deep into Candel's promising work in viral immunotherapies for cancers and the unique leadership and management philosophies that have guided his journey. Additionally, Paul Peter touches on his passion for leveraging collective intelligence and his unconventional hobbies that keep him grounded and creative. 00:00 Introduction and Guest Welcome00:59 Early Career and Passion for Medicine02:09 Transition to Industry and GSK Experience04:50 Building Successful Organizations07:42 Innovative Models in Pharma19:03 Joining Candel Therapeutics and Vision for the Future25:15 Transforming Cancer Treatment27:24 Challenges in Biotech Market28:45 Strategic Decisions and Prioritization31:39 Collaborations and External Partnerships33:07 Innovative Approaches and Future Prospects44:23 Leadership and Personal Insights Don't forget to Like, Share, Subscribe, Rate, and Review! Keep up with Paul Peter Tak;LinkedIn: https://www.linkedin.com/in/paul-peter-tak-md-phd-fmedsci-1b44749/ Follow Mike Rea On;Website: https://www.ideapharma.com/X: https://x.com/ideapharmaLinkedIn: https://www.linkedin.com/in/bigidea/ Listen to more fantastic podcast episodes: https://podcast.ideapharma.com/

In this episode of Idea Collider, we sit down with Susan Galbraith from AstraZeneca, a leading figure in oncology R&D. Susan shares her journey from medical training in Manchester and Cambridge to spearheading transformative cancer treatments at AstraZeneca. She discusses pivotal moments in her career, AstraZeneca's vision for eliminating cancer as a cause of death, the role of patient stories in motivating R&D efforts, and the integration of emerging technologies like AI and digital health tools.  With a focus on collaboration and continuous learning, Susan provides insights into how successful oncology drugs are developed and the importance of equitable representation in clinical trials. Stay tuned for an engaging conversation that highlights the future of personalized cancer therapies and the collaborative efforts driving innovations in oncology.Chapter Summaries;00:00 Introduction and Guest Welcome00:27 Susan Galbraith's Career Journey02:37 Defining Success in Oncology R&D05:01 Early Phase Drug Development07:09 Digital Health and Patient Experience12:37 Global Collaboration and Innovation15:05 AI and Future of Oncology28:08 Diversity and Inclusion in Clinical Trials33:46 Mentorship and Career Advice37:45 Challenges and Future Outlook in Oncology42:06 Closing Remarks and Call to Action Don't forget to Like, Share, Subscribe, Rate, and Review! Keep up with Susan Gabraith;LinkedIn: https://www.linkedin.com/in/susan-galbraith-584a195/?originalSubdomain=uk Follow Mike Rea On;Website: https://www.ideapharma.com/X: https://x.com/ideapharmaLinkedIn: https://www.linkedin.com/in/bigidea/ Listen to more fantastic podcast episodes: https://podcast.ideapharma.com/

In this episode of IDEA Collider, we dive into the world of biotech innovation with John Maraganore, former CEO of Alnylam Pharmaceuticals. Recognized as a trailblazer, John transformed RNA interference from a scientific concept into a revolutionary class of medicines, leading the development of five life-changing drugs. Join us as we explore John's journey from a first-generation American with Greek immigrant parents to a key figure in biomedicine. We'll discuss his education at the University of Chicago, his leadership role at Alnylam, drug delivery challenges for RNAi therapeutics, and the importance of strategic pharmaceutical alliances. John also shares his take on the current biotech environment, the impact of policy and regulation, and the promising future of genetic medicines and AI in drug discovery. Chapter Summaries;00:00 Introduction to John Maraganore: Biotech Trailblazer01:11 John's Early Life and Education03:09 Joining Alnylam and the RNAi Revolution04:56 Challenges and Successes at Alnylam06:47 Current Biotech Funding Environment08:17 Global Competition and US Leadership in Biotech10:25 The Importance of In-Person Collaboration12:01 Overcoming Drug Delivery Hurdles15:21 Maintaining an Entrepreneurial Spirit in Biotech17:00 Balancing Science and Business in Decision Making20:27 Strategic Partnerships in Biotech23:36 The Role of Biotech in Global Challenges26:25 Advocating for Policy Changes in Biotech30:41 Mentoring the Next Generation of Biotech Leaders32:35 Future Frontiers in Biotech Innovation36:08 John's Vision for the Future of Biomedicine37:18 Communicating Innovation and LeadershipDon't forget to Like, Share, Subscribe, Rate, and Review! Keep up with John Maraganore;LinkedIn: https://www.linkedin.com/in/john-maraganore/ Follow Mike Rea On;Website: https://www.ideapharma.com/X: https://x.com/ideapharmaLinkedIn: https://www.linkedin.com/in/bigidea/ Listen to more fantastic podcast episodes: https://podcast.ideapharma.com/

We are excited to tell you more about the IDEA Pharma and Exploristics partnership. IDEA's COO, Jacqui Barendregt, asked Exploristics Founder and CEO Aiden Flynn five key questions about the innovative service model and, most importantly, the value to the pharmaceutical industry this newly formed partnership will bring.

Welcome to another episode of Idea Collider with your host, Mike Rea. In this engaging conversation, we delve into the world of pharmaceutical innovation and collaboration. Our guest, Dr. Nedim Pipic, a pharmaceutical expert specializing in mental and retinal health, shares his journey and passion for making a difference. Join us as we explore the unmet needs in these areas, the power of hybrid approaches and precision psychiatry, and the integration of digital therapeutics. Discover how the industry is transforming lives through innovation while remaining patient-centric. With insights into measuring development quality, the advantages of being a private company, and the importance of collaboration, this episode will inspire you to embrace change and drive positive outcomes in the pharmaceutical landscape. Tune in to Idea Collider today and be part of the movement toward a healthier, sustainable, and equitable future. Chapter Summaries [0:00:21] Introduction to today's guest, Dr. Nedim Pipic [0:04:23] Discussion on Innovation and Growth Mindset [0:06:44] Innovation and Patient Benefit in the Pharmaceutical Industry: A Discussion on the Importance of Return on Invention and Understanding Unmet Needs in Mental Health [0:08:25] Innovating Mental Health: A Discussion on Precision Psychiatry and Unmet Patient Needs [0:14:39] A Discussion on Precision Medicine and the Importance of Understanding Neurobiology in Addressing Symptoms [0:16:39] Driving Innovation in Pharma: Importance of Early Research Collaborations and Agile Culture [0:18:52] Discussion on Innovation and R&D in Pharmaceutical Industry [0:20:22] Driving Innovation and Culture in a Private Pharmaceutical Company [0:23:41] Insights on Innovation and Transformation [0:25:46] The Importance of Seeking Inspiration Outside of the Pharma Industry: A Conversation on AI and Agile Transformation [0:27:04] A Discussion on the Intersection of Medicine and Business in Pharmaceutical Innovation [0:33:28] Discussion on the Future of the Pharma and Biotech Industry and the Importance of Innovation and Collaboration [0:36:06] The Future of the Pharma Industry: Collaboration, Patient Empowerment, and Sustainability [0:37:39] Closing Remarks Don't forget to Like, Share, Subscribe, Rate, and Review! Keep up with Dr. Nedim Pipic; ● LinkedIn: https://www.linkedin.com/in/nedim-pip... ● Website: http://www.boehringer-ingelheim.com Follow Mike Rea On; ● Website: https://www.ideapharma.com/ ● Twitter: https://twitter.com/ideapharma ● LinkedIn: https://www.linkedin.com/in/bigidea/ Listen to more fantastic podcast episodes: https://podcast.ideapharma.com/ Don't forget to Subscribe, Rate, Review, Like, and Share! To listen to more fantastic podcast episodes: https://podcast.ideapharma.com/

Welcome to another incredible episode of the IDEA Collider│Pharma Book Club series with your host Mike Rea. Today, Annie Duke joins us on the show to discuss her latest book, “Quit: The Power of Knowing When to Walk Away.” Annie is an Author, Professional Speaker, Decision Strategist & co-founder of The Alliance for Decision Education, a non-profit whose mission is to improve lives by empowering students through decision skills education. In the episode, Annie Duke delves into the motivation behind her latest book, “Quit,” when quitting is a valuable option rather than sticking around, grit versus willingness to quit, and Stewart's Butterfield's Quit story before founding Slack. In addition, Annie expounds on the fear of changing your mind and why most people worry about failing instead of winning. Ultimately, she delves into the Monkey & Pedestal Model, three reasons behind building the pedestal, the kill criteria & why you should have a quitting coach! Tune in for more! During this episode, you will learn about; [00:00:33] Introducing today's guest [00:01:37] What motivated Annie in writing her book Quit as opposed to Thinking in Bets that lead to decision making [00:06:40] The difference between grit & willingness to quit [00:09:27] Why eight times more people die on the descent of Mt. Everest than climbing [00:18:53] Muhammad Ali is the embodiment of showing how in one circumstance, Grit can be a virtue & in the other circumstance, a downfall [00:30:20] Stewart Butterfield's story from one of the world's greatest quitter to founding Slack [00:39:37] The fear of changing your mind & failing[00:48:36] The monkey & pedestal model [00:56:18] Three reasons behind building the pedestal [01:02:38] The kill criteria  & the idea of having a quitting coach [01:10:08] Does Annie act as a quitting coach? [01:18:51] The Reverse Sicilian concept [01:20:17] How to connect with Annie Duke Don't forget to Follow, Rate, Review, Like, and Share Mentioned BooksThinking in Bets by Annie DukeQuit: The Power of Knowing When to Walk Away by Annie DukeGrit by Angela DuckworthInto Thin Air by Jon Krakauer Let's Connect! Follow Alliance For Decision Education;Website: https://alliancefordecisioneducation.org/ Follow Annie Duke;Website: https://www.annieduke.com/Twitter: https://twitter.com/AnnieDukeLinkedIn: https://www.linkedin.com/in/annie-duke/ More ProductsFollow Mike Rea on;Website: https://www.ideapharma.com/Twitter: https://twitter.com/ideapharmaLinkedIn: https://www.linkedin.com/in/bigidea/ To listen to more amazing podcast episodes: https://podcast.ideapharma.com/

Welcome to another incredible episode of the IDEA Collider series with your host Mike Rea. Today the Chief Financial Officer at Recursion, Dr. Michael Secora, joins us on the show as we discuss the industrial revolution of drug discovery. Michael is a scientist and a former equity investor.In the episode, Michael delves into the reasons behind the incredibly fast growth at Recursion, the company's mission of decoding biology to radically improve lives, the relatability of data, and how Recursion builds its various data sets for drug discovery. Moreover, he expounds on how Recursion stands out against its competitors in the tech industry, the unique demographics of the Recursion team, and what differentiates Recursion from other AI discovery companies.Tune in!During this episode, you will learn about;[00:23] Introducing today's episode[01:29] About Michael Secora and Recursion as it is today[04:58] Recursion's Mission on decoding biology to improve lives radically[08:48] Biotechnology versus BioPharma Companies[15:00] Relatability of Data[17:10] Recursion's data sets & their contents[22:13] How many terabytes of data are they in executing each experiment[24:15] How Recursion stands out against competitors in the Tech environment[26:23] Michael's approach to humility in the pharmaceutical industry[28:28] Demographics of the Recursion team[31:20] Recursion's Hack Week[34:51] The difference between AI discovery companies & Recursion[40:11] A hint of Recursion incredible speed in delivering value proposition[47:47] Michael's Book Recommendations[50:16] How to connect with Michael & Recursion` Don't forget to Follow, Rate, Review, Like, and Share! Mentioned BooksJourney through Mathematics by Enrique A. GonzalezTeam of Teams by Gen. Stanley McChrystal, Tantum Collins, David Silverman & Chris FusselWhat is Life by SchrodingerLet's Connect!Follow Recursion on;Website: https://www.recursion.com/LinkedIn: https://www.linkedin.com/company/recursion-pharmaceuticals/ Follow Michael SecoraLinkedIn: https://www.linkedin.com/in/michael-secora-phd/ More ProductsFollow Mike Rea on;Website: https://www.ideapharma.com/Twitter: https://twitter.com/ideapharmaLinkedIn: https://www.linkedin.com/in/bigidea/ To listen to more amazing podcast episodes: https://podcast.ideapharma.com/

The healthcare industry is moving towards a digital revolution. With the help of digital technology, healthcare providers can now provide better and more efficient services to their patients. Digital technology has also proven to have a positive impact on patient outcomes, as well as the cost of care. Companies such as Openwater, which focuses on creating the future of medical imaging, have been able to deliver life-saving technologies. Through the use of low-intensity ultrasound, Openwater has been able to treat diseases such as glioblastoma, depression, neurodegenerative diseases, and stroke.In this episode, Mary Lou Jepsen, the CEO and Founder of Openwater shares how Openwater started and what it deals with. Mary Jepsen also shares how her company has transformed healthcare through digital technology. Moreover, she discusses the operating and hiring principles of the company.   Tune in for more insights! Key Highlights[01:44] Meet our guest; Meet our guest; Mary Lou Jepsen, and hear her backstory[03:32] The contrast between Pharmaceutical Companies and companies such as Google & Facebook[05:18] How we can apply physics to create interference ability and be able to see into our bodies using camera chips used in smartphones instead of using huge and expensive MRI scanners[07:32] Why the One Laptop Per Child (OLPC) initiative didn't work[09:35] How she co-created the world's first holographic video system from an idea that seemed impossible  [12:07] Physicists' predominant culture of looking for all the ways that they might be wrong and learning from that vs. Biologists' culture of looking for any proof that they are right [17:05] Technology that uses low-intensity ultrasound on human brain organoids in glioblastoma cancer treatment which is better than chemotherapy [18:24] How did Openwater start, and what does the company deal with? [20:17] The use of technology to enable rapid identification of the large vessel occlusions to decrease the time to intervention in stroke victims[26:56] Severe depression treatment using a headset capable of focusing low-frequency ultrasound on the nerve cells in the brain, which is more effective than transcranial magnetic stimulation[31:42] The side effect of psychedelics in depression treatment  [37:00] Comparison between cost change in the consumer electronics industry and the healthcare industry  [40:21] The operating and hiring principles of the Openwater company[49:00] How to link with Mary Lou Jepsen Don't forget to Follow, Rate, Review, Like, and Share! Let's Connect!Follow Mary Lou Jepsen on her;Personal website:https://www.maryloujepsen.com/Company website: https://www.openwater.cc/LinkedIn: https://www.linkedin.com/in/majepsen/Twitter: https://twitter.com/mljmljmljFacebook: https://web.facebook.com/maryloujepsen?_rdc=1&_rdr More Products Follow Mike Rea on;Website: https://www.ideapharma.com/Twitter: https://twitter.com/ideapharmaLinkedIn: https://www.linkedin.com/in/bigidea/ To listen to more fantastic podcast episodes: https://podcast.ideapharma.com/

Welcome to another incredible episode of the IDEA Collider│Pharma Book Club series with your host Mike Rea. Today a competitive advantage expert, and CEO of Smart Advantage, Jaynie Smith, joins us on the show.  She delves into snippets in her book, Creating Competitive Advantage, & the role of competitive advantage in increasing sales and protecting profit margins. Moreover, she explains that it's not about prices but your value proposition, understanding your customers' top three buying criteria, and competitive positioning.  Ultimately she discusses the power of competitive advantage, implementing metrics that quantify competitive ads and focusing on the company rather than product advantage.Tune in for more! During this episode, you will learn about;[00:20] Introducing today's episode[01:27] About today's guest, “Jaynie Smith.”[05:05] The process of unpacking & looking for opportunities[09:44] Does everyone in business understand why they are in business[11:45] Competitive advantage is closing deals & making money in an organization[13:43] Why companies don't spend enough time listening to their customers[16:09] Building your value proposition[22:28] Competitive positioning[26:05] Do people give positioning the credit  that's due in the business world[30:48] Do ad agencies get competitive positioning right?[32:20] Company versus product competitive advantage[35:57] Why companies  lose sight of things that matter most to their customers[38:52] Persistence in communication[40:58] How to connect with Jaynie Smith[41:40] Book recommendations from Jaynie Let's Connect!Follow Jaynie Smith on;LinkedIn: https://www.linkedin.com/in/jayniesmith/Website: jayniesmith.comFollow Smart AdvantageWebsite: https://smartadvantage.com/More ProductsFollow Mike Rea on;Website: https://www.ideapharma.com/Twitter: https://twitter.com/ideapharma LinkedIn: https://www.linkedin.com/in/bigidea/To listen to more amazing podcast episodes: https://podcast.ideapharma.com/

Welcome to another incredible episode of the IDEA Collider│Pharma Book Club series with your host Mike Rea. Today we are joined by Sherine Khalil, the Vice President and Chief Business Officer for Valor Compounding Pharmacy. She talks about sterile and non-sterile compounding as well as her transition from the nonprofit world to academic medicine.Additionally, she delves into the major functional areas of compounding pharmacy, the reasons behind the decline in compounding pharmacy over the years, her source of ideas, and how she judges success. Moreover, Sherine expounds on the organizational structure within the pharmacy, how far she plans into the future, and her journey in business consulting. Tune in! During this episode, you will learn about;[01:23] About Sherine Khalil[05:36] Sherine's transition from the nonprofit world to academic medicine[11:25] Is her curiosity self-directional?[13:55] About compounding pharmacy and its major function areas[15:55] Reasons for the decline in compounding pharmacy over the years[19:00] Sherine's source of ideas. What's her process of assessing development[21:10] Organizational structure  and hierarchy within the pharmacy[22:25] How she judges success. What will work or not work[23:54] How far Sherine plans into the future[28:06] What her Quarter 1 & 2 goals look like for her amidst covid in 2022[30:13] What's in Sherine's organizational structure that makes her more agile than other companies[32:19] Sherine's biggest idea in telehealth[39:33] Sherine's journey in business consultancy[44:29] Her source of motivation[46:36] Sherine's book recommendations[48:04] One thing Sherine wishes she could have been asked[52:13] To connect with Sherine Let's Connect!Follow Sherine Khalil on;LinkedIn: https://www.linkedin.com/in/sherinekhalilEmail: skhalil@vcprx.comFollow Valor Compounding Pharmacy;Website: https://valorcompounding.com/More ProductsFollow Mike Rea on;●        Website: https://www.ideapharma.com/●        Twitter: https://twitter.com/ideapharma●        LinkedIn: https://www.linkedin.com/in/bigidea/To listen to more amazing podcast episodes: https://podcast.ideapharma.com/

Welcome to another incredible episode of the IDEA Collider│Pharma Book Club series with your host Mike Rea. Today we are joined by Prof. Brian D Smith, a pharma innovation geek for the past 24 years. He talks about his latest book, “ New Drugs, Fair Prices,” and how to manage the pharmaceutical innovation ecosystem for sustainable and affordable new medicines.Additionally, he delves deep into discovery habitats and how every habitat contributes to the ecosystem for a sustainable and affordable supply of new medicines. Moreover, Brian expounds on an unhealthy ecosystem and three big goals to achieve in our ecosystems.Tune in!During this episode, you will learn about;[00:21] Introducing the show[01:17] About Brian Smith[04:41] Brian's main focus in his latest book, “New Drugs, Fair Prices.”[09:20] A snippet of the introduction to Brian's new book[14:58] Why the definition of terms was important all the way through his book[18:36] The selection pressure in the industry[18:57] The seven types of habitats and what they need to contribute to the ecosystem[22:30] The innovation habitat[25:00] Brian's definition of an unhealthy ecosystem[28:46] Three big goals we need to achieve through our ecosystem[33:20] Ecosystems don't just change. How do you understand and manage them?[42:00] Book recommendations for aspiring innovation and pharmaceutical geeks[46:52] How to connect with Brian SmithLet's Connect!Follow Brian Smith on;Website: https://www.pragmedic.com/Youtube: https://www.youtube.com/watch?v=35HFWM6tbTcPodcast: https://podcasts.apple.com/us/podcast/darwins-medicine/id1551652841More ProductsFollow Mike Rea on;●        Website: https://www.ideapharma.com/●        Twitter: https://twitter.com/ideapharma●        LinkedIn: https://www.linkedin.com/in/bigidea/To listen to more amazing podcast episodes: https://podcast.ideapharma.com/

Welcome to another incredible episode of the IDEA Collider│Pharma Book Club series with your host Mike Rea. Today a tech pioneer, founder & CEO of Rapid Alpha joins us on the show as we discuss marketing intelligence & why business leaders can not ignore data quality. Matthew talks about his career path from intellectual property to where he is now, about Rapid Alpha, what innovation management entails, and how data works and impacts company decisions. Additionally, he expounds on the right KPIs for pharmaceuticals, platforms & tools for better data organization, creating value for your company as well as the future of data.Tune in for more!During this episode, you will learn about;[00:27] Introducing the episode[00:40] Know our guest “Matthew Wahlrab”[04:47] His career path from intellectual property to where he is now[12:00] How data works[16:55] Defining innovation management[21:16] How data impacts company decisions[22:15] About Matthew's company Rapid Alpha & what they do[24:48] Matthew's special sources [26:29] Matthew's approach to Green flags & who should be working where[29:49] Getting your timing right[32:22] The right KPIs for pharmaceuticals[37:49] Platforms & tools for better data organization[43:04] Creating value in an enterprise[47:52] The future of data[51:44] Book recommendations from Matthew[55:45] Best way to connect with Matthew Wahlrab[56:31] One question he wishes to have been askedLet's Connect!Follow Matthew Wahlrab on;LinkedIn: https://www.linkedin.com/in/matthew-wahlrab/Follow Rapid Alpha on;Website: https://rapidalpha.com/LinkedIn: https://www.linkedin.com/company/rapidalpha/ More ProductsFollow Mike Rea on;●        Website: https://www.ideapharma.com/●        Twitter: https://twitter.com/ideapharma●        LinkedIn: https://www.linkedin.com/in/bigidea/To listen to more amazing podcast episodes: https://podcast.ideapharma.com/

Welcome to another incredible episode of the IDEA Collider│Pharma Book Club series with your host Mike Rea. Today, Tim Kight,  a long-life student of elite performance, coach, and Focus 3 CEO joins us on the show as we discuss developing leaders & strengthening organizational culture to achieve better results.Tim delves into the five drivers of organizational greatness, training your team on behavioral skills, rebuilding your company's culture, and expanding your focus run. Additionally, he talks about replacing old habits with good ones, the twenty square ft principle, and stepping up to become an elite in your team! Tune in for more! During this episode, you will learn about;[00:27] Introducing the show[01:50] Tim's background & experience in sports & business[05:45] Invention doesn't become innovation all by itself.  What roles teams & organizations play[07:29] 5 drivers for organizational greatness[09:25] Talent recognition in organizations[11:26] What to consider when hiring -Job skills vs. behavior skills. [17:52] Leading with your heart in business[20:43] Rethinking & rebuilding a company's clear, concise & compelling culture[23:13] A quick contrast between an athletic & business team[26:41] Planning for the future of your business.  The known versus the unknown of the company's future.[31:14] Expanding your focus run & 5 questions to ask yourself and your team[35:50] Unlearning to relearn your skill versus replacing old habits with good ones[38:00] Tim's twenty square ft principle[45:37] A case study on changing culture, discipline & achieving good results[53:00] Stepping up, confronting that default mode, and becoming elite in your team[55:36] To connect with Tim Kight Don't forget to Follow, Rate, Review, Like, and Share! Let's Connect!Follow Tim Kight on;●        LinkedIn: https://www.linkedin.com/in/timothykight/●        Website:  https://focus3.com●        Twitter: @TimothyKight●        Email: tim@foucs3.comMore ProductsFollow Mike Rea on;●        Website: https://www.ideapharma.com/●        Twitter: https://twitter.com/ideapharma●        LinkedIn: https://www.linkedin.com/in/bigidea/To listen to more amazing podcast episodes: https://podcast.ideapharma.com/

Welcome to another amazing episode of the IDEA Collider│Pharma Book Club series with your host Mike Rea. In today's episode, Mike is joined by John Waid. John is a thought leader, author, and CEO of a unique boutique global culture & leadership development firm. He talks about culture and the purpose of an organization.Additionally, he talks about the importance of knowing your; purpose, mission, values, and principles of behavior and why most professionals who are promoted based on their skill sets fail when promoted to leadership positions. Moreover, he shares how to start building a successful workplace culture.  Tune in! During this episode, you will learn about;[00:22] Episode introduction[00:36] Today's focus; Asymmetric learning and its impact on culture[00:55] Know our guest; John Waid[03:01] What is culture?[05:41] The purpose of an organization[10:36] Examples of companies and their values[14:46] Why he came up with the principle of three values[16:34] The importance of respectful spirit value[19:19] Why you should know your; purpose, mission, values, and principles of behavior[22:16] Why most professionals who are promoted based on their skillsets fail when promoted to leadership positions[26:27] Chick-fil-A's values and culture[32:31] Why one company outperforms the other[37:16] Can culture be built virtually? [40:25] How to start building a successful workplace culture [42:53] Disruption vs Innovation[45:09] How to connect with John Waid  Love the show? Follow, Rate, Review, Like, and Share!  Let's Connect!Follow John Waid on;Website: https://www.corporatecultureconsulting.com/LinkedIn: https://www.linkedin.com/in/johnwaid/Facebook: https://www.facebook.com/c3culture/ More Products Follow Mike Rea on;Website: https://www.ideapharma.com/Twitter: https://twitter.com/ideapharmaLinkedIn: https://www.linkedin.com/in/bigidea/To listen to more amazing podcast episodes: https://podcast.ideapharma.com/

Welcome to another incredible episode of the IDEA Collider│Pharma Book Club series with your host Mike Rea. Today we are joined by a consultant, best-selling author, and one of the world's top experts on strategy and innovation, Rita McGrath.In the episode, Rita talks to us about her transition from a political science career to innovation in the corporate venture, how to build an innovation program, challenges in implementation, and why you need multiple funding sources while championing an idea. Additionally, we delve into making that 10x shift in a company, discovery-driven planning, strategic inflection points & best books she would recommend.Tune in for more innovation insights![02:01] About Rita McGrath[05:10] Rita's books[11:55] Tips for building an innovation program[16:10] Why do companies have one innovation process[18:45] Reasons companies prefer false confidence instead of the uncertain approach[27:40] How to get an organization to make a shift to a big place[34:11] Rita's thoughts on creativity[37:25] Why you should have multiple sources  of funding & approval[37:54] Being future forward on failure & interrogating failure[43:48] Problems related to assumptions in planning[49:39] Discovery-driven planning[51:01] Strategic inflection points[55:05] Books Rita would recommend[57:16] This or that question (Disruption or innovation)[58:13] To connect with McGrath Mentioned BooksSeeing Around the Corners By Rita McGrathMarket Busters By Rita McGrathThe End of Competitive Advantage By Rita McGrathDiscovery-Driven Growth By Rita McGrathSeven Rules of Power By Jeffrey PfefferThinking Fast & Slow by Kahneman DanielHumor Seriously By Jennifer A Aker & Naomi Bagdonas Let's Connect!To Connect With Rita McGrath;●    Website: https://www.ritamcgrath.com/●    Website: https://www.valize.com/ More ProductsFollow Mike Rea on;Website: https://www.ideapharma.com/Twitter: https://twitter.com/ideapharmaLinkedIn: https://www.linkedin.com/in/bigidea/To listen to more amazing podcast episodes: https://podcast.ideapharma.com/

Welcome to another incredible episode of the IDEA Collider│Pharma Book Club series with your host Mike Rea. Today we are joined by Andrew Hopkins, the Founder & CEO  of Exscientia, as he talks to us about the use of AI in drug discovery. In the episode, we delve into Andrew's journey of developing better drug discovery methods, applying data mining in drug discovery, and the value of data integration in the pharmaceutical industry. Additionally, he expounds on what AI drugs look like and future plans for Exscientia. Tune in! During this episode, you will learn about;[01:12] Introducing Andrew Hopkins & his journey to his current role[06:27] Applying data mining approach & machine learning[12:10] What Andrew saw that others were not seeing[19:06] The value of data integration[22:02] The role of asking questions & finding answers in tech or data[26:46] How Hopkins addresses being referred to as the AI discovery group[33:08] Active learning approaches[39:06] What an AI drug looks like & what it's better at[42:17] The future of AI drugs & Exscientia future plans in establishing clinics[46:34] What do the next couple of years look like regarding solutions Andrew wished he had 5-10 years ago? Don't forget to Follow, Rate, Review, Like, and Share! Mentioned BooksIdeas-A History From Fire To Freud by Peter WatsonWhere Good Ideas Come From by Steven Johnson Let's Connect!Follow Exscientia on;●        Website: https://www.exscientia.ai/●    LinkedIn: https://www.linkedin.com/company/ex-scientia/ More ProductsFollow Mike Rea on;Website: https://www.ideapharma.com/Twitter: https://twitter.com/ideapharmaLinkedIn: https://www.linkedin.com/in/bigidea/ To listen to more amazing podcast episodes: https://podcast.ideapharma.com/

In this incredible episode, Mike Rea is joined by Dr. John L. LaMattina. John is the former Senior Vice President of Pfizer Inc and President of Pfizer Global Research & Development. Additionally, he is a senior partner at PureTech Health and an author. He talks about the misconception about Pfizer's profiteering from the pandemic and the drug pricing in America. John also discusses how Gilead's Sovaldi drug for hepatitis C became overpriced in the US and the effects of insurance companies on the drug market. Moreover, he talks about the misinformation about insulin and its pricing, NIH's role in drug discovery research, and the profitability of the pharma industry.Tune in! During this episode, you will learn about;[00:22] Introduction to the show[0:42] Know our guest; Dr. John L. LaMattina, and why he has authored his books[04:58] Misconception about Pfizer's profiteering from the pandemic[08:13] Drug pricing in America[12:35] Gilead's Sovaldi drug for hepatitis C and how it became overpriced in the US more than in other countries [19:57] The cost-effectiveness of PCSK9 in regulating (low-density lipoprotein) LDL cholesterol[21:42] Effect the insurance companies have had on the drug market [26:09] Value of  the ‘me-too' drugs [30:01] The inefficiency of the flu vaccines [33:03] The funding for early-stage mRNA vaccines [34:23] The input of the FDA and CDC in the manufacture of mRNA vaccines [37:46] What is NIH's role in drug discovery research?[38:13] The process and cost of drug discovery; from idea to getting the drug approved[42:39] Misinformation about insulin and its pricing [47:21] Is the value vs. affordability of medicines a reputation challenge or a  commercial challenge for the industry?[51:31] What's the profitability of the pharma industry?[59:48] Recommended reading [01:02:38] How to connect with us Don't forget to Subscribe, Rate, Review, Like, and Share! Resources MentionedBook; Pharma and Profits by John L. LaMattina Book; Devalued and Distrusted by John L. LaMattinaBook; Drug Truths by John L. LaMattinaBook; The Great American Drug Deal by Peter Kolchinsky  Let's Connect!Website: https://www.johnlamattina.com/Twitter: https://twitter.com/john_lamattinaLinkedIn: https://www.linkedin.com/in/john-lamattina-2985a9b/ More Products Follow Mike Rea on;Website: https://www.ideapharma.com/Twitter: https://twitter.com/ideapharmaLinkedIn: https://www.linkedin.com/in/bigidea/ To listen to more fantastic podcast episodes: https://podcast.ideapharma.com/

Welcome to another fantastic episode of the IDEA Collider│Asymmetric learning series with your host Mike Rea. Today we are joined by Gene Yoo, the Chief Executive Officer at Resecurity, Inc. He talks about asymmetric learning in cybersecurity & Intelligence and what gives Resecurity an edge over other competitors in the marketMoreover, he shares about the signal validation process at Resecurity, how to understand the vulnerability of your business and what you need to combat cyber threats. In addition, Gene talks about the ‘what if' component in their learning approach and the leadership style & culture at Resecurity. Tune in! During this episode, you will learn about; [00:23] Introduction to the show[01:23] What this series is about; Asymmetric learning[04:41] Definition of insight in cybersecurity[07:07] What is cyber threat intelligence about, and how should threat intelligence data be interpreted to deliver actionable insights?[10:37] Security theater[14:40] How Resecurity identifies a threat [19:58] Understanding the vulnerability of your business and what you need to combat cyber threats[22:52] Do they provide threat solutions or just threat evidence?[24:22] The ‘what if' component in their learning approach [27:36] What gives Resecurity an edge over other cybersecurity & Intelligence companies in the market?[29:19] Signal validation process at Resecurity[31:00] The source of their data[34:29] Resecurity leadership style and culture[39:40] Prototyping at Resecurity[42:49] Does Gene prefer a disruptor or an innovator? [44:59] What's the future of  Resecurity in 5 years? (46:33] How to connect with Gene Yoo Don't forget to Subscribe, Rate, Review, Like, and Share! Let's Connect!Follow Gene Yoo on;Website: https://resecurity.com/LinkedIn: https://www.linkedin.com/company/resecurity/Facebook: https://bit.ly/3vqMfzSTwitter: https://twitter.com/RESecurityVimeo: https://vimeo.com/user153388997 More Products Follow Mike Rea on;Website: https://www.ideapharma.com/Twitter: https://twitter.com/ideapharmaLinkedIn: https://www.linkedin.com/in/bigidea/ To listen to more amazing podcast episodes: https://podcast.ideapharma.com/

Welcome to another fantastic episode of the IDEA Collider│Asymmetric learning series with your host Mike Rea. In today's episode, Mike interviews Steven Johnson, an author of 13 books, a TV host, and a podcaster. He talks about Innovation vs. Invention and explains where good ideas come from. Additionally, Steven talks about the Individual and organizational hunch collection tools and shares how organizational culture impacts innovation. Moreover, he talks about his books The Ghost Map and Farsighted. Tune in! During this episode, you will learn about;[01:05] Meet Steven Johnson and hear his backstory[03:03] Innovation vs. Invention[05:26] Where do good ideas ‘soul hunches' come from?[09:32] Reason why play and delight are linked to profound innovation[12:52] Organizational culture and innovation[17:12] How the daily schedule for his writing work looks like [10:1414] Steven's discovery process[26:59] How Steven uses Twitter as a source of scientific discovery[30:58] Individual and organizational hunch collection tools[39:10] The Ghost Map and how it evolved  from the format to a published book[46:34] Farsighted: How We Make the Decisions That Matter the Most[55:11] How to connect with Steven Johnson Remember to Follow, Rate, Review, Like, and Share! Resources MentionedBook; The Ghost Map by Steven JohnsonBook; Farsighted by Steven JohnsonBook; How We Got to Now by Steven JohnsonBook: Wonderland by Steven Johnson  Let's Connect!Follow Steven Johnson on;Website: https://stevenberlinjohnson.com/Twitter: https://twitter.com/stevenbjohnsonSubscribe to his Newsletter at: https://adjacentpossible.substack.com/aboutTo grab a copy of any of Steven's Books: https://amzn.to/3L3zUrV More Products Follow Mike Rea on;Website: https://www.ideapharma.com/Twitter: https://twitter.com/ideapharmaLinkedIn: https://www.linkedin.com/in/bigidea/To listen to more fantastic podcast episodes: https://podcast.ideapharma.com/

Welcome to another fantastic episode of the IDEA Collider│Pharma Book Club series with your host Mike Rea. Today we are joined by Billy Kenber, an investigative journalist at “The Times.” He talks about his journey to writing his book ‘Sick Money' and the content in the book.Additionally, he talks about the pharmaceutical industry's social contract with patients and how its distortion has led to pharmaceutical greed. Moreover, he shares how the culture within the pharmaceutical industry has changed, why drug companies overprice the drugs, and what can be done to regulate drug pricing. Tune in! During this episode, you will learn about; [00:22] Episode introduction[01:08] Meet our guest; Billy Kenber[01:22] His journey to writing his book ‘Sick Money'[03:28] What the book is about[06:11] How Concordia Pharmaceuticals & Valeant Pharmaceuticals companiesgrew quickly and gained a short-term monopoly, thus hiking the drug prices[10:40] What's the geographical scope of the pharmaceutical fraud[12:47] Pharmaceutical industry's social contract with patients and how its distortion has led to pharmaceutical greed[15:20] The first AIDS drug; AZT[18:30] A background of AZT drug high pricing and how it led to otherpharmaceutical companies raising their prices[22:47] How Pharmacy Benefit Managers (PBMs) raise drug prices for patients[25:39] The 'Dirty Pharma' chapter in his book[28:45] Why drug companies overprice the drugs[29:17] How the culture within the pharmaceutical industry has changed[30:52] Pharmaceutical innovation after World War II; Antibiotics[35:29] mRNA vaccines in the COVID-19 pandemic[37:28] Effect of cultural changes in the pharmaceutical industry on the drugs weget and how Research and Development (R&D) is done[40:30] How cultural changes have affected orphan drugs and cancer drugs[46:30] What can be done to regulate drug pricing?[53:50] Recommended reading[56:00] How to connect with Billy Love the show? Follow, Rate, Review, Like, and Share! Let's Connect! Follow Billy Kenber on his;Website: https://www.billykenber.com/  Twitter: https://twitter.com/billykenber Linkt.ree: https://linktr.ee/billykenber To grab a copy of the ‘Sick Money' book: https://amzn.to/3N4XJPD More ProductsFollow Mike Rea on;Website: https://www.ideapharma.com/ Twitter: https://twitter.com/ideapharma LinkedIn: https://www.linkedin.com/in/bigidea/To listen to more amazing podcast episodes: https://podcast.ideapharma.com/

Kabir Nath is President & CEO, Otsuka North America Pharmaceutical Business Throughout his career, Kabir has built bridges between cultures. His work has taken him across the globe, spanning 3 continents and multiple countries. Kabir has lived and worked in the United Kingdom, France, Spain, India, Singapore, China, and the United States. He has consistently inspired those around him to go beyond cultural and linguistic differences to bring new concepts and ideas to life, forging stronger partnerships rooted in diverse experiences. For Kabir, leadership is not about having all the answers, rather, it is about creating an environment where Otsuka-people are deeply connected to their purpose, and the patients and families they serve. In his nearly 30 years of broad international biopharmaceutical and medical-device experience, Kabir has shaped strategy to deliver results in complex, challenging business environments at the country, regional, and global level. Otsuka, with its unique blend of Japanese and American cultures, is the place where Kabir puts his purpose into practice daily. Kabir joined Otsuka in March 2016 to head all commercial operations within the North American pharmaceutical businesses. Most recently, Kabir was appointed Senior Managing Director, Global Pharmaceutical Business at Otsuka, with overall operational leadership for the global pharmaceutical business, overseeing North America, Europe, Japan, and the rest of Asia, while continuing to have direct responsibility for the US business. Before joining Otsuka, Kabir held strategic and senior operational roles across several continents at Bristol-Myers Squibb (BMS). He began his career in strategy consulting at Booz Allen & Hamilton before holding a wide range of operational and strategic roles at the medical technology company Smith + Nephew. Kabir holds an MA from King's College, University of Cambridge, and an MBA with Distinction from INSEAD.

 (Now also released in paperback: https://amzn.to/3lWjo2B) Kat can be found at First Create The Media:  and on Twitter: @Kat_Arney Find out more about Rebel Cell here: https://www.rebelcellbook.com/about-rebel-cell-cancer-bookMany of us think of cancer as a contemporary killer, a disease of our own making caused by our modern lifestyles. But, as Kat Arney explains in her new book REBEL CELL: Cancer Evolution and the Science of Life, that perception just isn't true. Although it might be rare in many species, cancer is the enemy lurking within almost every living creature. Why? Because cancer is a bug in the system of life. We get cancer because we can't not get it.Cancer has always been with us. It killed our hominid ancestors, the mammals they evolved from and the dinosaurs that trampled the ground before that. Tumours grow in pets, livestock and wild animals. Even tiny jelly-like Hydra - creatures that are little more than a tube full of water - can get cancer.Cancer starts when cells rebel against the social norms of the body, throwing off their molecular shackles and growing out of control in a shambolic mockery of normal life. This is why we can't avoid cancer: because the very genes that drive it are essential for life itself.The revolution has raged, on and off, for millions of years. But it was only in the twentieth century that doctors and scientists made any significant progress in understanding and treating cancer, and it is only in the past few decades that we've finally begun to kick the mob's malignant arse.Now the game is changing. Scientists have infiltrated cancer's cellular rebellion and are finally learning its secrets. Seeing cancer in a new way – as rebel cells adapting and evolving within the landscape of the body – is pointing towards new ways of preventing and controlling cancer in the long term or even driving it to extinction altogether.In REBEL CELL, geneticist and science writer Kat Arney reveals that:Modern lifestyles can't take all the blame – Cancer has been around for millions of years and affects almost all multicellular organisms, with some notable exceptions. Sponges and comb jellies are remarkably cancer-resistant, for example, although the reason why is still a mystery.Cancer cells are cheats that break the rules – From cells all the way up to human cities, societies function best when everyone obeys the rules. Cancer cells are cheats in the system, bending or completely breaking the rules to their advantage.Cancer is an inevitable part of life – Genetic alterations (mutations) are the fuel for evolution – the force that shaped all life on earth. But this same force is at work within cancer, enabling them to adapt and evolve resistance to treatment.Mutations are much more common than we thought – As we age, our bodies become a patchwork of mutated cells, yet most of these don't become cancerous. The big question is why?The quest for a cure has derailed our thinking – Focusing on ‘magic bullets' and pricey wonder drugs has led us away from potentially transformative approaches to preventing and treating cancer based on evolutionary ideas.REBEL CELL: Cancer Evolution and the Science of Life takes the reader back to the dawn of life on planet earth right up to the present day to get to the heart of what cancer really is and how by better understanding it we might one day overcome it.

As President of Novartis Oncology, Susanne Schaffert is pursuing a bold strategy to reimagine the research, development and commercialization of innovative treatments that will help improve and extend the lives of people with cancer and related blood disorders. Susanne has held positions of increasing seniority across a range of business areas during her career at Novartis, having first joined the company as a sales representative in Germany in 1995. The majority of her roles have been in oncology, where she has a passion for making a difference in the lives of patients. Prior to her current position, she served as President of Advanced Accelerator Applications, a Novartis company focused on the development of products for targeted radioligand therapy and precision imaging. Today, she leads more than 10 000 employees in 85 countries working to transform cancer care across four distinct therapeutic platforms. Susanne is a respected business leader and scientist who was featured in Fortune's “Most Powerful Women International” list in both 2019 and 2020. She actively mentors women at Novartis and encourages them to seek leadership roles. Susanne has a background in science and holds a doctorate in organic chemistry from the University of Erlangen in Germany, but as a former ballet dancer, she is also passionate about the arts. This dual interest informs her leadership philosophy, which celebrates diversity of thought and ideas as one of the keys to bold innovation. Susanne also holds leadership positions in the broader pharmaceutical industry. She serves on the board and executive committee of the European Federation of Pharmaceutical Industries and Associations (EFPIA), and is vice chair of EFPIA's Patient Access Committee. Susanne on LinkedIn: https://www.linkedin.com/in/susanne-schaffert-830b7053

Dan Skovronsky is the chief scientific officer of Eli Lilly and Company. He serves as senior vice president of science and technology and president of Lilly Research Laboratories. He also has responsibility for global business development. Dan joined Lilly in 2010 when the company acquired Avid Radiopharmaceuticals Inc., where he had been CEO since founding the company in 2004. At Lilly, Dan has held various roles, including vice president, tailored therapeutics; vice president, diabetes research; and most recently, senior vice president, clinical and product development. Dan completed his residency training in pathology and fellowship training in neuropathology at the Hospital of the University of Pennsylvania. He received his M.D. from the Perelman School of Medicine, University of Pennsylvania, in 2001 and his Ph.D. in Neuroscience from University of Pennsylvania in 2000. Dan earned a Bachelor of Science in molecular biophysics and biochemistry from Yale University in 1994..

With so much at stake in the application of AI/ Machine Learning to pharma, biotech and medicine, this wonderful book touches on biases, systems of learning, and the choices we have to make to properly harness the power of what is possible. Email mike at ideapharma.com to enter a lottery to win a copy of the hardcover book, closing date 26th February.From the page at brianchristian.org: A jaw-dropping exploration of everything that goes wrong when we build AI systems and the movement to fix them. Today’s “machine-learning” systems, trained by data, are so effective that we’ve invited them to see and hear for us—and to make decisions on our behalf. But alarm bells are ringing. Recent years have seen an eruption of concern as the field of machine learning advances. When the systems we attempt to teach will not, in the end, do what we want or what we expect, ethical and potentially existential risks emerge. Researchers call this the alignment problem. Systems cull résumés until, years later, we discover that they have inherent gender biases. Algorithms decide bail and parole—and appear to assess Black and White defendants differently. We can no longer assume that our mortgage application, or even our medical tests, will be seen by human eyes. And as autonomous vehicles share our streets, we are increasingly putting our lives in their hands. The mathematical and computational models driving these changes range in complexity from something that can fit on a spreadsheet to a complex system that might credibly be called “artificial intelligence.” They are steadily replacing both human judgment and explicitly programmed software. In best-selling author Brian Christian’s riveting account, we meet the alignment problem’s “first-responders,” and learn their ambitious plan to solve it before our hands are completely off the wheel. In a masterful blend of history and on-the ground reporting, Christian traces the explosive growth in the field of machine learning and surveys its current, sprawling frontier. Readers encounter a discipline finding its legs amid exhilarating and sometimes terrifying progress. Whether they―and we―succeed or fail in solving the alignment problem will be a defining human story. The Alignment Problem offers an unflinching reckoning with humanity’s biases and blind spots, our own unstated assumptions and often contradictory goals. A dazzlingly interdisciplinary work, it takes a hard look not only at our technology but at our culture―and finds a story by turns harrowing and hopeful. Read more at: https://brianchristian.org/the-alignment-problem/

 Syn is an award winning music agency and creative solutio, providing music strategy, composition, sound design and sonic branding for advertising, cinema and television, as well as music supervision, licensing and music curation services and our studios record voiceover, ADR and narration.In this interview, we discuss the user experience (patient, physician), via sound, for healthcare and pharma environmentsMore information at https://syn.world

Great interview with Riccardo on CNBCFind out more about PTEN Research at https://www.ptenresearch.org

Covering a wide variety of topics, with a special focus on Novartis as one of the best examples of a learning organisation in pharma. On cultures of innovation, 'unbossing', decision making and measuring what matters John can be found on LinkedIn: https://www.linkedin.com/in/john-tsai-md-ab398b4/ or contacted by email at john_tsai.office at novartis.com

A discussion of The Playbook, from DiMe Society, Digital Clinical Measures Introducing the essential industry guide for successfully developing & deploying digital clinical measures across clinical research, clinical care, and public health https://playbook.dimesociety.org More on Andy (Andrea) Coravos here: http://www.andreacoravos.com More on Jen (Jennifer) Goldsack here: https://en.wikipedia.org/wiki/Jennifer_Goldsack More on DiMe Society here: https://www.dimesociety.org

Carinne Brouillon is a Member of the Board of Managing Directors, with responsibility for the Human Pharma Business Unit Professional milestones 2018 – 2019 Global Head of Therapeutic Areas, Boehringer Ingelheim 2014 – 2018 Head of Global Commercial Strategy Neuroscience at Janssen, Johnson & Johnson’s Pharmaceutical Company 2012 – 2018 President of Janssen Therapeutics and Member of the Janssen North America Leadership Team Edward Hæggström Born 1969. Finnish citizen. Co-founder of Nanoform, CEO and a member of the Management Team since 2015. Education: Ph.D. degree in applied physics from the University of Helsinki and a Master of Business Administration degree in innovation management from Helsinki University of Technology. Experience: Dr. Hæggström has, among others, been a professor at the University of Helsinki and Head of the Electronics Research Laboratory within the Department of Physics. He has previously held the role of visiting professor of physics at Harvard Medical School, visiting scholar (assistant professor) of physics at Stanford University and project leader at the CERN. Rob Scott, MD, a trained physician, has held leadership positions in global pharmaceutical companies for thirty years. During his career he has managed drug development teams responsible for highly successful pharmaceutical brands such as Norvasc, Lipitor, Repatha, Humira, Skyrizi and Rinvoq. Before retiring, his most recent position was Chief Medical Officer and Head of Development at AbbVie where he had oversight on all early and late-stage development programs. He was also responsible for a team of over 4,000 employees spanning 52 countries, a budget of close to $2 billion and programs involving approximately 40 new molecular entities. Before that, he was Vice President, Global Development TA Head and Head of Development Design Center at Amgen where he was responsible for the development of evolocumab (Repatha) the first approved PCSK9 inhibitor, ivabradine (Corlanor), to treat heart failure and omecamtiv mecarbil, a direct myosin activator for heart failure. From 2012 - 2016 he was a member of the US Food and Drug Administration’s Cardiovascular and Renal Drug Advisory Committee where he built strong relationships with senior FDA staff. Before Amgen, he held several leadership positions with emerging pharmaceutical and biotech companies. Dr. Scott is a graduate from the University of Cape Town, South Africa and started his career at Janssen as a Medical Advisor. He is a board member of Transclerate and a member of the PhRMA R&D Leadership Forum.

This episode replays some of a round table we held at JP Morgan, back when people used to travel... It features the voices of Mike Rea, in conversation with Linda Avey, Co-founder of 23andMe, and Curious, Inc, Amrit Chaudhuri, CEO, Mass Innovation Labs (now SmartLabs), Steve Holtzman, then CEO, Decibel Therapeutics, Raj Kannan then SVP, Global Franchise Head, Neurology & Immunology, EMD Serono, Michael Schrage, Research Fellow, MIT Center for Digital Business; Visiting Fellow, Imperial College Department of Innovation and Entrepreneurship, and Robert Urban, then Global Head, Johnson & Johnson Innovation Do head to our YouTube channel for more from this round table, and to see which voice belongs to which speaker...

ABOUT THE INNOVATION DELUSION Innovation is the hottest buzzword in business. But what if our obsession with finding the next big thing has distracted us from the work that matters most? “The most important book I’ve read in a long time . . . It explains so much about what is wrong with our technology, our economy, and the world, and gives a simple recipe for how to fix it: Focus on understanding what it takes for your products and services to last.”—Tim O’Reilly, founder of O’Reilly Media It’s hard to avoid innovation these days. Nearly every product gets marketed as being disruptive, whether it’s genuinely a new invention or just a new toothbrush. But in this manifesto on thestate of American work, historians of technology Lee Vinsel and Andrew L. Russell argue that our way of thinking about and pursuing innovation has made us poorer, less safe, and—ironically—less innovative. Drawing on years of original research and reporting, The Innovation Delusion shows how the ideology of change for its own sake has proved a disaster. Corporations have spent millions hiring chief innovation officers while their core businesses tank. Computer science programs have drilled their students on programming and design, even though theoverwhelming majority of jobs are in IT and maintenance. In countless cities, suburban sprawl has left local governments with loads of deferred repairs that they can’t afford to fix. And sometimes innovation even kills—like in 2018 when a Miami bridge hailed for its innovative design collapsed onto a highway and killed six people. In this provocative, deeply researched book, Vinsel and Russell tell the story of how we devalued the work that underpins modern life—and, in doing so, wrecked our economy and public infrastructure while lining the pockets of consultants who combine the ego of Silicon Valley with the worst of Wall Street’s greed. The authors offer a compelling plan for how we can shift our focus away from the pursuit of growth at all costs, and back toward neglected activities like maintenance, care, and upkeep. For anyone concerned by the crumbling state of our roads and bridges or the direction our economy is headed, The Innovation Delusion is a deeply necessary reevaluation of a trend we can still disrupt.

Peter B. Bach is a physician, epidemiologist, researcher, and respected healthcare policy expert whose work focuses on the cost and value of anticancer drugs. Dr. Bach is leading efforts to increase understanding of the US drug development process and develop new models for drug pricing that include value to patients Dr. Bach described a 100-fold increase in cancer drug prices since 1965 after adjusting for inflation, and that the cost of an additional year of life from a cancer treatment increases by $8,500 each year. In 2012, he and other physicians at MSK drew attention to the high price of a newly approved cancer drug and announced his hospital’s unprecedented move not to offer it to patients because of its high price tag with no notable improved clinical outcomes. The drug price was later cut in half by the manufacturer. Dr. Bach’s work in lung cancer screening has led to the development of several lung cancer screening guidelines and one of the first-ever risk-prediction models for this disease. He has also proposed a number of strategies for Medicare to link payment to the value of healthcare services delivered. Dr. Bach has been inducted into the National Academy of Medicine, American Society of Clinical Investigators and the Johns Hopkins University Society of Scholars. He served as a Senior Advisor for Cancer Policy at the Center for Medicare and Medicaid Services in 2005 and 2006. Dr. Bach has published more than 100 peer-reviewed articles and editorials in scientific journals such as the New England Journal of Medicine and the Journal of the American Medical Association. He has also written numerous healthcare-related op-eds and been featured in mainstream media outlets such as the New York Times, New York magazine, the Wall Street Journal, Forbes, NPR, and 60 Minutes. View a comprehensive list of media coverage of Dr. Bach and his work. Dr. Bach completed his undergraduate studies at Harvard University and his medical studies at the University of Minnesota and the University of Chicago Harris School. He completed a residency in internal medicine at Johns Hopkins University followed by a fellowship in pulmonary and critical care medicine at the University of Chicago and Johns Hopkins. While at the University of Chicago, he was a Robert Wood Johnson Foundation Clinical Scholar. Dr. Bach has been a faculty member in MSK’s Department of Epidemiology and Biostatistics since 1998 and a Senior Scholar at the International Agency for Research on Cancer since 2008. In 2020, Dr. Bach co-founded EQRx, a biotechnology startup focused on developing affordable drugs. He currently serves an advisory role within the organization. Further information at: https://drugpricinglab.org/about/ or https://www.mskcc.org/news/media-coverage?keys=Peter+bach

In conversation, discussing patient input into clinical programs, unmet need assessments, measurement and so much more.Jen was diagnosed with juvenile arthritis as an infant and now has a laundry list of other conditions and surprises (like a brain tumor). She is passionate about elevating and valuing the patient voice, and went on to become a health outcomes researcher, human factors engineer, FDA Consumer Representative, and, most importantly, a patient advocate. Jen earned a PhD in Environmental Medicine from NYU, and studies patient-centered outcomes at Columbia University Medical Center. Jen can usually be found dodging NYC traffic on her bicycle, sitting next to you at a conference, or rocking out to '90s music - she does a sweet running man.Jen at IDEA's UnHerd event at 2020 JP Morganhttps://medium.com/@jhoronjeffhttps://www.savvy.coophttps://techcrunch.com/2020/02/14/this-co-op-wants-to-put-money-back-into-patients-hands/

From the Amazon description: Pharmaceutical breakthroughs such as anti­biotics and vaccines rank among some of the greatest advancements in human history. Yet exorbitant prices for life-saving drugs, safety recalls affecting tens of millions of Americans, and soaring rates of addiction and overdose on pre­scription opioids have caused many to lose faith in drug companies. Now, Americans are demanding a national reckoning with a monolithic industry. Pharma introduces brilliant scientists, in-corruptible government regulators, and brave whistleblowers facing off against company exec­utives often blinded by greed. A business that profits from treating ills can create far deadlier problems than it cures. Addictive products are part of the industry’s DNA, from the days when corner drugstores sold morphine, heroin, and cocaine, to the past two decades of dangerously overprescribed opioids. Pharma also uncovers the real story of the Sacklers, the family that became one of America’s wealthiest from the success of OxyContin, their blockbuster narcotic painkiller at the center of the opioid crisis. Relying on thousands of pages of government and corporate archives, dozens of hours of interviews with insiders, and previously classified FBI files, Posner exposes the secrets of the Sacklers’ rise to power—revelations that have long been buried under a byzantine web of interlocking companies with ever-changing names and hidden owners. The unexpected twists and turns of the Sackler family saga are told against the startling chronicle of a powerful industry that sits at the intersection of public health and profits. https://www.posner.com/pharma/ https://www.amazon.com/Pharma-Greed-Lies-Poisoning-America/dp/1501151894

PureTech Health is an advanced, clinical-stage biopharmaceutical company developing novel medicines targeting serious diseases that result from dysfunctions in the nervous, immune, and gastrointestinal systems (brain-immune-gut or the “BIG” axis), which together represent the adaptive human systems. PureTech Health is at the forefront of understanding and addressing the biological processes and crosstalk associated with the BIG axis. By harnessing this emerging field of human biology, the Company is pioneering new categories of medicine with the potential to have great impact on people with serious diseases. PureTech Health is advancing a rich pipeline that includes multiple post human proof-of-concept studies and pivotal stage programs. PureTech’s rich research and development pipeline has been advanced in collaboration with some of the world’s leading scientific experts, who along with PureTech’s team of biopharma pioneers, entrepreneurs and seasoned Board, identify, invent, and clinically de-risk new medicines. With this experienced team pursuing cutting edge science, PureTech Health is building the biopharma company of the future focused on improving and extending the lives of people with serious disease. Ms. Zohar created PureTech Health, assembling a leading team to help implement her vision for the Company. Ms. Zohar has been recognized as a top leader and innovator in biotechnology by a number of sources, including EY, BioWorld, MIT’s Technology Review, the Boston Globe, and Scientific American. She sits on the Technology Development Fund Advisory Board at Children’s Hospital Boston, is an Editorial Advisor to Xconomy, and is on the Board of Advisors of Life Science Care 

25 Visions for the Future of Our Species We now have the tools to transform ourselves and our species. Greater health and longevity, enhanced brains, and engineered fertility are in the works. What’s just over the horizon is even more astonishing. We call this the neobiological frontier. The book is a collection of 25 essays, interviews, and works of fiction and art offering a big-picture perspective on the profound changes made possible by the merging of biology and technology. The book brings together today's smartest and most creative inventors, thinkers, and scientists to tell us their vision of the future. This book is a 2020 time capsule for future humans. Neo.Life: 25 Visions for the Future of Our Species covers these powerful new biotechnologies and ideas in non-technical language, with beautiful full-color images and a fresh design by National Design Award winner Jennifer Morla. This book makes a compelling foundation for the discussions we’ll be having about these technologies for years to come, and as one observer said, it is definitely coffee table worthy, no matter which planet that table is on. Meet George Church, one of the most prodigious bioengineers of our time, in conversation with Ramez Naam, a computer scientist, clean tech investor, and science fiction author. George maintains a list of genes that could be edited to make humans healthier or more suited to future environmental conditions, including life off-planet. He’s also got an idea to send a single-cell biological probe to faraway worlds that could be programmed to beam information back to Earth. Consider neuroscientist David Eagleman’s ideas about how embryo selection could change the way we parent our children. Dive into an imagined future with inventor Danny Hillis as he guides you through the possibilities and pitfalls of designing your child from scratch using gene editing technology. Will you “supersize” them, or give them an extra appendage? If you bestow a color or pattern, keep in mind that it might be trendy today but look dated 10 years from now. Discover filmmaker and artist Lynn Hershman Leeson’s ideas about identity in her antibody-as-art project that will change how you think about life-science technologies. Hear from Osh Agabi, the Swiss-Nigerian roboticist-neuroscientist who’s built a brain on a chip, literally blending silicon and neurons. He envisions using his technology to allow us to connect our consciousnesses together in a sort of giant empathy web. Read Juan Enriquez, who has been thinking and writing about self-directed evolution for a long time. In his creative brief, he imagines a future with a far greater diversity of human species, and considers the implications. Ponder the risks and ethical implications of this new frontier with CRISPR scientist and film producer Samira Kiani, who outlines the safety checks she’s developing to control gene edits. And hear from biosecurity policy expert Megan Palmer, who shares how her experiences led to social responsibility programs for synthetic biologists. BOOK DETAILS Designed by Jennifer Morla Hardcover, 7 3/4 x 9 3/4 inches 160 pages, 25 color illustrations Smyth sewn, with silver Litho foil-stamped cover Contributors: Oshiorenoya Agabi, Christina Agapakis, Siranush Babakhanova, Seth Bannon, George Church, Emma Conley, Zoe Cormier, Zack Denfeld, Heather Dewey-Hagborg, David Eagleman, Juan Enriquez, Kristen Fortney, Joel Garreau, Daisy Ginsberg, Danny Hillis, Samira Kiani, Cathrine Kramer, Becky Lyon, Hannu Rajaniemi, Lux Alptraum, Lynn Hershman Leeson, Ramez Naam, Megan Palmer, Nicola Patron, Robert Plomin, Steve Ramirez, Sissel Tolaas, Bowen Zhao, Changle Zhou.

Chapter-by-chapter discussion, covering:opium/ heroinantibioticscontraceptive pillvaccinesand more...Find more by Thomas Hager here: https://www.thomashager.net 

Dr. Jeremy M. Levin is Chairman and CEO of Ovid Therapeutics Inc (NASDAQ:OVID), a company whose mission is to bring treatment to patients with rare neurological conditions. Dr. Levin is concurrently the chairman of the Biotechnology Innovation Organization (BIO). Prior to founding Ovid, Dr. Levin was president and CEO of Teva Pharmaceutical Industries Ltd., (TLV: TEVA) Before Teva, Dr. Levin was member of the executive committee Bristol-Myers Squibb Company (NYSE: BMY). In that capacity he was the architect of and implemented the String of Pearls Strategy, which transformed Bristol. Dr. Levin joined BMY from Novartis (SWX: NOVN) where he was global head of strategic alliances. He has served on the board of directors of various public and private biopharmaceutical companies and is currently on the board of directors of Lundbeck (OMX: LUN). Dr. Levin was voted as one of the twenty-five most influential biotechnology leaders by Fierce Biotech and one of the top three biotechnology CEOs in 2020 by The Healthcare Technology Report. He is the recipient of the Albert Einstein Award for Leadership in Life Sciences and the B’nai B’rith Award for Distinguished Achievement. He has practiced medicine at university hospitals in England, South Africa, and Switzerland. Dr. Levin earned his bachelor’s degree in zoology and a master’s degree and doctorate in chromatin structure, at the University of Oxford, and thereafter his medical and surgical degrees from the University of Cambridge where he won the Kermode Prize for his work on Captopril. Authors of individual chapters HISTORICAL PERSPECTIVES Vicki L. Sato, Stelios Papadopoulos, Sam Waksal, Bill Sibold, Frederick Frank Q&A with a Biotech Pioneer, Brook Byers, Sol Barer PERSONAL PERSPECTIVES Michelle McMurry-Heath, Andy Plump, Kiran Mazumdar-Shaw, Karen Bernstein, Ron Cohen, Samantha Du, Cedric François THE VIEW FROM INSIDE COMPANIES George Scangos, John Young, Stéphane Bancel, Jean-Pierre Sommadossi, John V. Oyler, Paul Hastings, Christi Shaw, John Maraganore, Rachel King, Richard Pops, Deborah Dunsire BROAD LESSONS Kenneth I. Moch, Quita Highsmith, Luke Rosen, Sylvia Wulf, Philip Miller, Alex Zhavoronkov and Evelyne Bischof LEADERSHIP Jeffrey M. Solomon, Julie Louise Gerberding, Jeff Berkowitz, James Greenwood INVESTOR PERSPECTIVES Nina Kjellson, Bruce Booth, Alexander Karnal, Mark Lampert, Geoff Porges LOOKING TO THE FUTURE Peter Kolchinsky, Yaron Werber, Jeff Kindler, Otello Stampacchia

The books Annie recommends:Maria KonnikovaThe Biggest Bluff: How I Learned to Pay Attention, Master Myself, and Win Philip Tetlock, Dan GardnerSuperforecasting: The Art and Science of Prediction Don A MoorePerfectly Confident: How to Calibrate Your Decisions Wisely

Peter on Twitter: https://twitter.com/peterkolchinskyThe book's website: https://peterkolchinsky.com/bioLink to the Katherine Eban discussion: 

Deborah Waterhouse, CEO ViiV Healthcare Deborah was appointed to GSK’s Corporate Executive Team on 8th January 2020. She became Chief Executive Officer of ViiV Healthcare on 1st April 2017. ViiV Healthcare is majority owned by GSK, with Pfizer Inc. and Shionogi Limited as shareholders. In this interview, we discuss cultures of innovation, innovation in the business model, purpose-driven innovation and more Deborah joined GSK in 1996 and was most recently the Senior Vice President of Primary Care within the company’s US business, prior to which she led the US Vaccines business. She brings a wealth of experience to GSK having lived and worked in Europe, Asia Pacific and the USA, and a strong track record of performance in both specialty and primary care. Deborah led the HIV business in the UK before heading the HIV Centre of Excellence for Pharma Europe, and held international roles as General Manager of Australia and New Zealand and Senior Vice President for Central and Eastern Europe.

For more on JLABS, go to https://jlabs.jnjinnovation.com/JLABSNavigator#/As Global Head of Johnson & Johnson Innovation, JLABS (JLABS), Melinda Richter fosters the Johnson & Johnson Family of Companies external R&D engine and supports the innovation community by creating capital-efficient commercialization models that give early stage companies a big company advantage. By providing infrastructure, services, educational programs and networks in global hotspots, JLABS is the best place to start a company working in healthcare, with a specific emphasis on Johnson & Johnson’s sectors: consumer, medical device and pharmaceuticals.Prior to joining JLABS, Melinda was Founder and CEO of Prescience International, an award-winning firm dedicated to accelerating research to the patient. Melinda founded Prescience after she had a medical emergency that left her questioning the efficiency and efficacy of the healthcare system. With the tenacity and resolve of a patient looking for a better solution, she set out to create a better model, which now forms the basis for JLABS’ operational infrastructure. Prior to starting Prescience, Melinda held posts across a variety of functional areas with a global corporation, Nortel Networks, in locations such as Research Triangle Park, New York, Toronto, London, Hong Kong and Beijing before arriving in San Francisco. She also initiated, raised capital and secured large corporate deals for several companies in both the life science and technology space. She holds a Bachelor of Commerce from the University of Saskatchewan in Canada and a MBA from INSEAD in France. Melinda is an active board member and Treasurer of the California Life Sciences Association (CLSA). 

In an archive recording, from 2015, the author of one of the best pharma-related books of the past decade, Clifton Leaf, gives us an insight into The Truth In Small Doses, Why We're Losing the War on Cancer-and How to Win It. (In this case, archive means that we thought we had lost the file, and then found it in a place we didn't expect!) Clifton, now Editor In Chief at Fortune Magazine, remains one of the most interesting voices in healthcare

Links to the papers we discussDiagnosing the Decline of Pharmaceutical R&D efficiency (2012): https://www.nature.com/articles/nrd3681When Quality Beats Quantity: Decision Theory, Drug Discovery, and the Reproducibility Crisis (2016): https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0147215Pharmaceutical Evolution: Clinical Selection versus Intelligent Design: https://www.innogen.ac.uk/sites/default/files/2019-08/Innogen-Working-Paper-115.pdfJack can be contacted at jack.scannell@btinternet.comThen the books Jack refers to:Robert Gordon: The Rise and Fall of American GrowthJames Le Fanu: The Rise and Fall of Modern MedicineDino Buzzati: The Tartar Steppe

Discussion of the new Matt Ridley book, How Innovation Works, published in May 2020. http://www.mattridley.co.uk Matt Ridley's books have sold over a million copies, been translated into 31 languages and won several awards. His books include The Red Queen, The Origins of Virtue, Genome, Nature via Nurture, Francis Crick, The Rational Optimist and The Evolution of Everything. His TED talk "When Ideas Have Sex" has been viewed more than two million times. He writes a weekly column in The Times (London) and writes regularly for the Wall Street Journal. As Viscount Ridley, he was elected to the House of Lords in February 2013. He served on the science and technology select committee 2014-2017. With BA and DPhil degrees from Oxford University, Matt Ridley worked for the Economist for nine years as science editor, Washington correspondent and American editor, before becoming a self-employed writer and businessman.

Why Boston/ Cambridge and South San Francisco?Why not New York?Cultures of innovationThe new way, scaling start-upsCritical factors for biotech hubsEurope/ The UK and the rest of the worldWhere does innovation come from? How is it defined?

Interview with Vinayak K. Prasad, author of Malignant: How Bad Policy and Bad Evidence Harm People with Cancer An essential listen for anyone involved in cancer R&D. Vinay is one of the more interesting voices on Twitter (@VPrasadMDMPH), and the book presents a wonderful exploration of what's right with oncology R&D and what's wrong. The interview reveals how positively he sees the opportunity to refocus on what matters to oncologists, and more importantly, to patients. The book is published in late April 2020, so I'd recommend a pre-order to ensure you get it on the day of release. From the book's website (http://www.vinayakkprasad.com/books) Each week, people read about new and exciting cancer drugs. Some of these drugs are truly transformative, offering major improvements in how long patients live or how they feel—but what is often missing from the popular narrative is that, far too often, these new drugs have marginal or minimal benefits. Some are even harmful. In Malignant, hematologist-oncologist Dr. Vinayak K. Prasad writes about the many sobering examples of how patients are too often failed by cancer policy and by how oncology is practiced. Throughout this work, Prasad illuminates deceptive practices which: • promote novel cancer therapies long before credible data are available to support such treatment • exaggerate the potential benefits of new therapies, many of which cost thousands and in some cases hundreds of thousands of dollars Prasad then critiques the financial conflicts of interest that pervade the oncology field, the pharmaceutical industry, and the US Food and Drug administration. This is a book about how the actions of human beings—our policies, our standards of evidence, and our drug regulation—incentivize the pursuit of marginal or unproven therapies at lofty and unsustainable prices. Prasad takes us through how cancer trials are conducted, how drugs come to market, and how pricing decisions are made, asking how we can ensure that more cancer drugs deliver both greater benefit and a lower price. Ultimately, Prasad says, • more cancer clinical trials should measure outcomes that actually matter to people with cancer; • patients on those trials should look more like actual global citizens; • we need drug regulators to raise, not perpetually lower, the bar for approval; and • we need unbiased patient advocates and experts. This well-written, opinionated, and engaging book explains what we can do differently to make serious and sustained progress against cancer—and how we can avoid repeating the policy and practice mistakes of the past.